2026-2034年mRNA治療藥物合約開發與生產組織（CDMO）全球市場規模、佔有率、趨勢和成長分析報告

全球mRNA療法合約開發與生產（CDMO）市場預計將從2025年的141億美元成長至2034年的412.6億美元，2026年至2034年的複合年成長率（CAGR）為12.67%。該市場正經歷顯著成長，主要得益於製藥和生物技術公司擴大將傳訊RNA療法的開發和生產外包。 CDMO在製程開發、分析測試、製劑和大規模生產方面提供專業知識，從而加速創新療法的商業化進程。基因治療、感染疾病治療、癌症研究和個人化醫療領域投資的不斷增加，也推動了該市場的強勁擴張。

合約研發生產機構（CDMO）正大力投資於最先進的生產設施、脂質奈米顆粒技術和高品質的生產能力，以滿足日益成長的市場需求。隨著生技創新者與專業生產商合作的不斷深入，生產規模化能力不斷提升，研發週期也不斷縮短。監管方面的專業知識、先進的品管系統和靈活的生產能力正成為至關重要的競爭優勢。臨床研發管線的擴展以及對RNA藥物的持續研究，不斷創造巨大的成長機會。

隨著mRNA技術的應用範圍從疫苗擴展到癌症、罕見疾病和慢性病的治療，其前景依然十分光明。人工智慧（AI）驅動的製程最佳化、連續生產和自動化品管將提高生產效率和一致性。製藥業外包的增加和對先進療法投資的加大將支持市場的長期發展。持續創新將進一步提升專注於mRNA的合約研發生產機構（CDMO）的全球策略地位。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球mRNA治療藥物合約開發與生產組織（CDMO）市場：按應用領域分類

• 市場分析、洞察與預測
• 病毒疫苗
• 蛋白質替代療法
• 癌症免疫療法
• 再生醫學

第5章：全球mRNA治療藥物合約開發與生產組織（CDMO）市場：依適應症分類

• 市場分析、洞察與預測
• 癌症
• 感染疾病
• 代謝紊亂與遺傳性疾病
• 心血管和腦血管疾病

第6章：全球mRNA治療藥物合約開發與生產組織（CDMO）市場：依最終用戶分類

• 市場分析、洞察與預測
• 生技公司
• 製藥公司
• 政府和學術研究機構

第7章 全球mRNA治療藥物合約開發與生產組織（CDMO）市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Thermo Fisher Scientific
  • Eurofins Scientific
  • WuXi Biologics
  • Samsung Biologics
  • Catalent
  • Rentschler Biopharma
  • AGC Biologics
  • Recipharm
  • Siegfried Holding
  • Boehringer Ingelheim
  • FUJIFILM Diosynth Biotechnologies
  • Lonza
  • Curia Global

The global mRNA therapeutics contract development & manufacturing organization market size is expected to reach USD 41.26 Billion in 2034 from USD 14.10 Billion in 2025, growing at a CAGR of 12.67 during 2026-2034.This market is witnessing exceptional growth as pharmaceutical and biotechnology companies increasingly outsource the development and manufacturing of messenger RNA therapeutics. Contract development and manufacturing organizations provide specialized expertise in process development, analytical testing, formulation, and large-scale production, enabling faster commercialization of innovative therapies. Rising investments in genetic medicine, infectious disease treatments, oncology research, and personalized therapeutics are driving strong market expansion.

CDMOs are investing heavily in advanced manufacturing facilities, lipid nanoparticle technologies, and high-quality production capabilities to meet growing demand. Increasing collaboration between biotechnology innovators and specialized manufacturers is improving production scalability while reducing development timelines. Regulatory expertise, advanced quality systems, and flexible manufacturing capacity are becoming essential competitive advantages. Expanding clinical pipelines and ongoing research into RNA-based medicines continue creating significant growth opportunities.

The future outlook remains highly promising as mRNA technology expands beyond vaccines into treatments for cancer, rare diseases, and chronic conditions. Artificial intelligence-driven process optimization, continuous manufacturing, and automated quality control will improve production efficiency and consistency. Rising pharmaceutical outsourcing and increasing investment in advanced therapeutics will support long-term market development. Continuous innovation will reinforce the strategic importance of mRNA-focused CDMOs worldwide.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Application

• Viral Vaccines
• Protein Replacement Therapies
• Cancer Immunotherapies
• Regenerative Medicine Therapy

By Indication

• Cancer
• Infectious Diseases
• Metabolic and Genetic Diseases
• Cardiovascular and Cerebrovascular Diseases

By End User

• Biotechnology Companies
• Pharmaceutical Companies
• Government and Academic Research Institutes

COMPANIES PROFILED

• Thermo Fisher Scientific, Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent, Rentschler Biopharma, AGC Biologics, Recipharm, Siegfried Holding, Boehringer Ingelheim, FUJIFILM Diosynth Biotechnologies, Lonza, Curia Global

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA THERAPEUTICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Viral Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Protein Replacement Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cancer Immunotherapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Regenerative Medicine Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MRNA THERAPEUTICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Metabolic and Genetic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Cardiovascular and Cerebrovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MRNA THERAPEUTICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Government and Academic Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MRNA THERAPEUTICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Application
  • 7.2.2 By Indication
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Application
  • 7.3.2 By Indication
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Application
  • 7.4.2 By Indication
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Application
  • 7.5.2 By Indication
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Application
  • 7.6.2 By Indication
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MRNA THERAPEUTICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Thermo Fisher Scientific
  • 9.2.2 Eurofins Scientific
  • 9.2.3 WuXi Biologics
  • 9.2.4 Samsung Biologics
  • 9.2.5 Catalent
  • 9.2.6 Rentschler Biopharma
  • 9.2.7 AGC Biologics
  • 9.2.8 Recipharm
  • 9.2.9 Siegfried Holding
  • 9.2.10 Boehringer Ingelheim
  • 9.2.11 FUJIFILM Diosynth Biotechnologies
  • 9.2.12 Lonza
  • 9.2.13 Curia Global